Learning a patient's specific situation might help overcome adherence barriers.
Lisa Holle, PharmD, BCOP, FHOPA
Advertisement
Articles by Lisa Holle, PharmD, BCOP, FHOPA
Betrixaban has been approved by the FDA for patients at risk for thromboembolisms.
Advertisement
Latest Updated Articles
Betrixaban for Prophylaxis of Venous ThromboembolismJune 4th 2018
Duvelisib for Relapsed or Refractory CLL/SLLJanuary 22nd 2019
Opinion: Pharmacists Are Best Suited to Improve AdherenceFebruary 26th 2019
Advertisement
Advertisement
Trending on Drug Topics
1
McKesson Partners with Pharmacies to Grow, Navigate Challenges
2
Finerenone Reduces Cardiovascular, Kidney Events Among Patients with T2D, CKD
3
FDA Approves Olezarsen as First Treatment to Reduce Pancreatitis Risk in Adults with Hypertriglyceridemia
4
HHS Claims ACIP Cannot Meet for Flu Season Due to Ongoing Legal Battle
5